Clinical study of combination therapy with high-dose moxibustion for herpes zoster/postherpetic neuralgia

Clinical study on the treatment of herpes zoster/post-neuralgia based on comprehensive moxibustion therapy based on ''Huo Yu Fa Zhi''

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050090

Enrollment

Unknown

Registered

2021-08-16

Start date

2021-08-09

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster, postherpetic neuralgia

Interventions

Group A (Herpes stage, scab stage treatment group):Fire acupuncture + Ashi point peripheral acupuncture combined with electric acupuncture + heavy moxibustion +blood-letting puncture and cupping

Group B (Treatment group for postherpetic neuralgia):Fire acupuncture + Ashi point peripheral acupuncture + heavy moxibustion + Jiaji point electroacupuncture +blood-letting puncture and cupping

Group C (Herpes stage, scab stage control group):Fire acupuncture +Ashi point peripheral acupuncture combined with electric acupuncture + conventional moxibustion +blood-letting puncture and cupping

Group D (Control group for postherpetic neuralgia):Fire acupuncture + Ashi point peripheral acupuncture + Jiaji point electroacupuncture +blood-letting puncture and cupping

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria of traditional Chinese and Western medicine for herpes zoster; 2. Aged 18-70 years, no gender limit; 3. Visual analog scale (VAS) score >= 4 points before treatment, and no relevant treatment within one week before enrollment; 4. Herpes occurs on the body and limbs; 5. Those who voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients; 2. Patients who are unable to express their own symptoms voluntarily, or have disorders of consciousness, coagulation disorders, and sensory disorders; 3. Allergic constitution or allergic to acupuncture; 4. Patients with serious primary diseases; 5. Progressive malignant tumor or other serious wasting disease, easy to be complicated by infection and bleeding; 6. Those with other diseases that cause pain; 7. Those who are participating in other clinical trials recently.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale;Prevalence of postherpetic neuralgia;	—

Secondary

Measure	Time frame
Shingles transient pain scale;Health-related quality of life assessment;Pittsburgh sleep quality index;Self-rating depression scale;Self-rating anxiety scale;	—

Countries

China

Contacts

Public ContactWu Jie

Chengdu University of Traditional Chinese Medicine

drwujie@163.com+86 18981885750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026